Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.
Recent studies have shown that intratumoral heterogeneity (ITH) is prevalent in clear cell renal cell carcinoma (ccRCC), based on DNA sequencing and chromosome aberration analysis of multiple regions from the same tumor. VHL mutations were found to be universal throughout individual tumors when it o...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0164554 |
id |
doaj-3c27cad578b342119a607b0d945cf870 |
---|---|
record_format |
Article |
spelling |
doaj-3c27cad578b342119a607b0d945cf8702021-03-04T12:55:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011110e016455410.1371/journal.pone.0164554Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.Wei JiangEssel DulaimiKarthik DevarajanTheodore ParsonsQiong WangLili LiaoEun-Ah ChoRaymond O'NeillCharalambos SolomidesStephen C PeiperJoseph R TestaRobert UzzoHaifeng YangRecent studies have shown that intratumoral heterogeneity (ITH) is prevalent in clear cell renal cell carcinoma (ccRCC), based on DNA sequencing and chromosome aberration analysis of multiple regions from the same tumor. VHL mutations were found to be universal throughout individual tumors when it occurred (ubiquitous), while the mutations in other tumor suppressor genes tended to be detected only in parts of the tumors (subclonal). ITH has been studied mostly by DNA sequencing in limited numbers of samples, either by whole genome sequencing or by targeted sequencing. It is not known whether immunohistochemistry (IHC) can be used as a tool to study ITH. To address this question, we examined the protein expression of PBRM1, and PBRM1-related proteins such as ARID1A, SETD2, BRG1, and BRM. Altogether, 160 ccRCC (40 per stage) were used to generate a tissue microarray (TMA), with four foci from each tumor included. Loss of expression was defined as 0-5% of tumor cells with positive nuclear staining in an individual focus. We found that 49/160 (31%), 81/160 (51%), 23/160 (14%), 24/160 (15%), and 61/160 (38%) of ccRCC showed loss of expression of PBRM1, ARID1A, SETD2, BRG1, and BRM, respectively, and that IHC could successfully detect a high prevalence of ITH. Phylogenetic trees were constructed that reflected the ITH. Striking co-losses among proteins were also observed. For instance, ARID1A loss almost always accompanied PBRM1 loss, whereas BRM loss accompanied loss of BRG1, PBRM1 or ARID1A. SETD2 loss frequently occurred with loss of one or more of the other four proteins. Finally, in order to learn the impact of combined losses, we compared the tumor growth after cells acquired losses of ARID1A, PBRM1, or both in a xenograft model. The results suggest that ARID1A loss has a greater tumor-promoting effect than PBRM1 loss, indicating that xenograft analysis is a useful tool to investigate how these losses impact on tumor behavior, either alone or in combination.https://doi.org/10.1371/journal.pone.0164554 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wei Jiang Essel Dulaimi Karthik Devarajan Theodore Parsons Qiong Wang Lili Liao Eun-Ah Cho Raymond O'Neill Charalambos Solomides Stephen C Peiper Joseph R Testa Robert Uzzo Haifeng Yang |
spellingShingle |
Wei Jiang Essel Dulaimi Karthik Devarajan Theodore Parsons Qiong Wang Lili Liao Eun-Ah Cho Raymond O'Neill Charalambos Solomides Stephen C Peiper Joseph R Testa Robert Uzzo Haifeng Yang Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. PLoS ONE |
author_facet |
Wei Jiang Essel Dulaimi Karthik Devarajan Theodore Parsons Qiong Wang Lili Liao Eun-Ah Cho Raymond O'Neill Charalambos Solomides Stephen C Peiper Joseph R Testa Robert Uzzo Haifeng Yang |
author_sort |
Wei Jiang |
title |
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. |
title_short |
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. |
title_full |
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. |
title_fullStr |
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. |
title_full_unstemmed |
Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. |
title_sort |
immunohistochemistry successfully uncovers intratumoral heterogeneity and widespread co-losses of chromatin regulators in clear cell renal cell carcinoma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Recent studies have shown that intratumoral heterogeneity (ITH) is prevalent in clear cell renal cell carcinoma (ccRCC), based on DNA sequencing and chromosome aberration analysis of multiple regions from the same tumor. VHL mutations were found to be universal throughout individual tumors when it occurred (ubiquitous), while the mutations in other tumor suppressor genes tended to be detected only in parts of the tumors (subclonal). ITH has been studied mostly by DNA sequencing in limited numbers of samples, either by whole genome sequencing or by targeted sequencing. It is not known whether immunohistochemistry (IHC) can be used as a tool to study ITH. To address this question, we examined the protein expression of PBRM1, and PBRM1-related proteins such as ARID1A, SETD2, BRG1, and BRM. Altogether, 160 ccRCC (40 per stage) were used to generate a tissue microarray (TMA), with four foci from each tumor included. Loss of expression was defined as 0-5% of tumor cells with positive nuclear staining in an individual focus. We found that 49/160 (31%), 81/160 (51%), 23/160 (14%), 24/160 (15%), and 61/160 (38%) of ccRCC showed loss of expression of PBRM1, ARID1A, SETD2, BRG1, and BRM, respectively, and that IHC could successfully detect a high prevalence of ITH. Phylogenetic trees were constructed that reflected the ITH. Striking co-losses among proteins were also observed. For instance, ARID1A loss almost always accompanied PBRM1 loss, whereas BRM loss accompanied loss of BRG1, PBRM1 or ARID1A. SETD2 loss frequently occurred with loss of one or more of the other four proteins. Finally, in order to learn the impact of combined losses, we compared the tumor growth after cells acquired losses of ARID1A, PBRM1, or both in a xenograft model. The results suggest that ARID1A loss has a greater tumor-promoting effect than PBRM1 loss, indicating that xenograft analysis is a useful tool to investigate how these losses impact on tumor behavior, either alone or in combination. |
url |
https://doi.org/10.1371/journal.pone.0164554 |
work_keys_str_mv |
AT weijiang immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT esseldulaimi immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT karthikdevarajan immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT theodoreparsons immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT qiongwang immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT lililiao immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT eunahcho immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT raymondoneill immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT charalambossolomides immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT stephencpeiper immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT josephrtesta immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT robertuzzo immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma AT haifengyang immunohistochemistrysuccessfullyuncoversintratumoralheterogeneityandwidespreadcolossesofchromatinregulatorsinclearcellrenalcellcarcinoma |
_version_ |
1714801061465686016 |